Evidence map›Paper›PMID 39600705›Full record

SynthesisFrontiers in immunology2024

Mevalonate kinase deficiency: an updated clinical overview and revision of the SHARE recommendations.

Lilla Lengvári, Kata Takács, Anna Lengyel, Annamária Pálinkás, Carine Helena Wouters, Isabelle Koné-Paut, Jasmin Kuemmerle-Deschner, Jerold Jeyaratnam, Jordi Anton, Helen Jane Lachmann and 13 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Case Report: Clinical application of anFrontiers in pediatrics · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Lilla LengváriPaediatric Centre, Semmelweis University, Budapest, Hungary.
Kata TakácsPaediatric Centre, Semmelweis University, Budapest, Hungary.
Anna LengyelPaediatric Centre, Semmelweis University, Budapest, Hungary.
Annamária PálinkásPaediatric Centre, Semmelweis University, Budapest, Hungary.
Carine Helena WoutersDepartment of Pediatrics, University Hospitals Leuven, Leuven, Belgium.
Isabelle Koné-PautDepartment of Pediatric Rheumatology, National Reference Centre for Rare Autoinflammatory Diseases and Inflammatory Amyloidosis, Centre Hospitalier Universitaire de Bicêtre, Assistance Publique-Hôpitaux de Paris, University of Paris Saclay, Le Kremlin-Bicêtre, France.
Jasmin Kuemmerle-DeschnerPediatric Rheumatology, Department of Pediatrics and Autoinflammation Reference Center, University Hospital Tuebingen, Tuebingen, Germany.
Jerold JeyaratnamDivision of Woman and Infant, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, Netherlands.
Jordi AntonDepartment of Pediatric Rheumatology, Hospital Sant Joan de De´ u, University of Barcelona, Barcelona, Spain.
Helen Jane LachmannNational Amyloidosis Centre, University College London, and Royal Free Hospital London NHS Foundation Trust, London, United Kingdom.
Marco GattornoUOC Reumatologia e Malattie Autoinfiammatorie, IRCCS Istituto G. Gaslini, Genoa, Italy.
Michael HoferPediatric Rheumatology and Immunology, Hoˆ pital Riviera-Chablais, Rennaz, Switzerland.
Nataša ToplakDepartment of Allergology, Rheumatology and Clinical Immunology, University Children's Hospital Ljubljana, University Medical Centre Ljubljana, Ljubljana, Slovenia.
Peter WeiserDivision of Rheumatology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, United States.
Tilmann KallinichDepartment of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charite´ - Universitätsmedizin Berlin, Berlin, Germany.
Seza OzenDepartment of Pediatric Rheumatology, Hacettepe University, Ankara, Türkiye.
Véronique HentgenFrench Reference Center for AutoInflammatory Diseases and Amyloidosis, Department of Pediatrics, Versailles Hospital, Versailles, France.
Yosef UzielPediatric Rheumatology Unit, Meir Medical Center, Tel Aviv University School of Medicine, Tel Aviv, Israel.
Zsuzsanna HorváthPaediatric Centre, Semmelweis University, Budapest, Hungary.
Márton SzabadosPaediatric Centre, Semmelweis University, Budapest, Hungary.
Paul Brogan *Inflammation & Rheumatology Section, UCL Great Ormond St Institute of Child Health, University College London, London, United Kingdom.
Tamás Constantin *Paediatric Centre, Semmelweis University, Budapest, Hungary.
Joost Frenkel *Division of Pediatrics, Wilhelmina Children's Hospital University Medical Center Utrecht, Utrecht, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mevalonate kinase deficiency (MKD), a rare auto-inflammatory disorder, arises from mutations in the

Indexed as

Mevalonate Kinase DeficiencyHumansMutationPhosphotransferases (Alcohol Group Acceptor)Practice Guidelines as Topicmevalonate kinasePhosphotransferases (Alcohol Group Acceptor)diagnosisgeneticsguidelinemevalonate kinase deficiencytreatment

Identifiers

PMID39600705
PMCPMC11590122

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.